Why MorphoSys leans on Monjuvi, the lymphoma drug that must deliver

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 23:51. Details in the imprint.

With Monjuvi, oncologists get a lymphoma drug that does not scream for attention in the infusion room but aims for one very specific task - helping patients with stubborn diffuse large B-cell lymphoma who have run out of standard options. The anti-CD19 antibody is meant to slot into real-world chemo routines, not tear them up. For MorphoSys, this quiet workhorse is anything but low profile.

What Monjuvi is designed to do

Monjuvi is a humanized monoclonal antibody targeting CD19, developed by MorphoSys and commercialized in the US together with Incyte. It is approved in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for transplant.

The drug is marketed as Monjuvi in the US and Minjuvi in Europe, where it received a conditional EU authorization in a similar patient population. Both authorizations are based on the single-arm phase 2 L-MIND trial, which tested tafasitamab plus lenalidomide in heavily pretreated patients.

How it is used in everyday oncology

In practice, Monjuvi is given as an intravenous infusion alongside oral lenalidomide over up to 12 cycles, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. The regimen is intensive initially, with more frequent infusions in the first cycles before the rhythm slows.

Oncologists appreciate that the combination can be delivered in community cancer centers without the complex logistics of CAR-T cell therapies. Infusion chairs, monitoring and nursing staff are still needed, but there is no need for specialized cell-handling facilities or individual manufacturing slots.

Efficacy and side-effect profile

In L-MIND, tafasitamab plus lenalidomide achieved an overall response rate of around 60 percent, with about 40 percent complete responses in transplant-ineligible relapsed or refractory DLBCL. Median duration of response surpassed two years in the updated analyses, which impressed many hematologists given the difficult setting.

The flip side is a predictable but relevant toxicity profile, dominated by hematologic side effects such as neutropenia, anemia and thrombocytopenia. These often require dose adjustments, growth-factor support or treatment interruptions, and they translate directly into more blood counts and conversations in the treatment room.

Competition and pricing pressure

Monjuvi moves in a fiercely contested second-line and later-line DLBCL landscape alongside CAR-T therapies from Gilead and Novartis, antibody-drug conjugates such as polatuzumab vedotin and other targeted combinations. Payers scrutinize every new entrant on survival benefit, quality of life and cost per patient.

List prices for tafasitamab plus lenalidomide are high, reflecting biologic manufacturing and niche oncology economics. However, CAR-T therapies still sit above that range, which gives Monjuvi a window to position itself as a more accessible option for patients who cannot or will not undergo cell therapy.

Where Monjuvi still has to prove itself

Regulators in both the US and Europe expect confirmatory data to underpin the current approvals, which are based on a single-arm study rather than randomized head-to-head evidence. That raises the bar for future readouts and keeps a degree of uncertainty over the long-term label.

Real-world data will be crucial. Oncologists want to see whether the robust response rates from L-MIND translate into everyday hospital practice, with older, frailer and more heterogeneous patients than in controlled trial settings.

Why the product matters for MorphoSys

For MorphoSys, Monjuvi is more than a product name on a packaging line. It is a recurring revenue stream that helps fund an ambitious, capital-intensive pipeline of oncology candidates, even as new owner Royalty Pharma focuses on maximizing existing assets.

Shares of MorphoSys (DE0006632003) trade on Xetra, where the company remains listed as an oncology-focused biotech despite the completed takeover by Royalty Pharma.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.